Literatur: Bridging

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

  • 1. Ralf Eisele, Nima Melzer, Cornelia Englert, Peter Bramlage, Michael Spannagl. Bridging mit dem niedermolekularen Heparin Certoparin bei Patienten, bei denen eine vorübergehende Unterbrechung der oralen Antikoagulation erforderlich ist – die nicht-interventionelle, retrospektive REMEMBER-Studie. Thrombosis Research 2012. [PDF]
  • 2. Bauersachs, Rupert M.; Schellong, Sebastian; Haas, Sylvia; Gogarten, Wiebke; Riess, Hanno; Omran, Heyder. Überbrückung der oralen Antikoagulation bei interventionellen Eingriffen. Dtsch Arztebl 2007; 104(18): A-1237 / B-1101 / C-1053 [PDF]
  • 3. Jack Hirsh, MD, FCCP, Chair, Gordon Guyatt, MD, FCCP, Gregory W. Albers, MD, Robert Harrington, MD, FCCP, and Holger J. Schünemann, MD, PhD. Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133;71S-109S. [PubMed 18574259]
  • 4. H.M. Hoffmeister, C. Bode, H. Darius, K. Huber, K. Rybak, S. Silber. Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Kardiologe 2010; 4:365–374 [PDF]
  • 5. Douketis JD, Johnson JA, Turpie AG: Low-molecular-weight-heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004; 164:1319–26. [PubMed 15226166]
  • 6. Jafri SM: Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J 2004; 147: 3–15. [PubMed 14691412]
  • 7. Spandorfer J: The management of anticoagulation before and after procedures. Med Clin North Am 2001; 85: 1109–16. [PubMed 14691412]
  • 8. Omran H, Hammerstingl C, Schmidt H, von der Recke G, Paar WD, Luderitz B: A prospective and randomized comparison of the safety and effects of therapeutic levels of enoxaparin versus unfractionated heparin in chronically anticoagulated patients undergoing elective cardiac catheterization. Thromb Haemost 2003; 90: 267–71. [PubMed 12888874]
  • 9. Dunn AS, Turpie AG: Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med 2003; 163: 901–8. [PubMed 12719198]
  • 10. Mehra P, Cottrell DA, Bestgen SC, Booth DF: Management of heparin therapy in the high-risk, chronically anticoagulated, oral surgery patient: a review and a proposed nomogram. J Oral Maxillofac Surg 2000; 58: 198–202. [PubMed 10670599]
  • 11. Gerson LB, Gage BF, Owens DK, Triadafilopoulos G: Effect and outcomes of the ASGE guidelines on the periendoscopic management of patients who take anticoagulants. Am J Gastroenterol 2000; 95: 1717–24. [PubMed 10925974]
  • 12. Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB: An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am 1999; 81: 2–10. [PubMed 9973048]
  • 13. Wahl MJ: Dental surgery in anticoagulated patients. Arch Intern Med 1998; 158: 1610–6. [PubMed 9701094]
  • 14. Montalescot G, Polle V, Collet JP et al.: Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000; 101: 1083–6. [PubMed 10715251]
  • 15. Stellbrink C, Nixdorff U, Hofmann T et al.: Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation 2004; 109: 997–1003. [PubMed 14967716]
  • 16. Fanikos J, Tsilimingras K, Kucher N, Rosen AB, Hieblinger MD, Goldhaber SZ: Comparison of efficacy, safety, and cost of low-molecular-weight heparin with continuous-infusion unfractionated heparin for initiation of anticoagulation after mechanical prosthetic valve implantation. Am J Cardiol 2004; 93: 247–50. [PubMed 14715362]
  • 17. Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM: Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1 year registry of 311 episodes. J Thromb Haemost 2005; 3: 2823–5. [PubMed 16359528]
  • 18. Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). J Am Coll Cardiol 2008 Oct 1;102(7):883-9. [PubMed 18805116]
  • 19. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E: The pharmacology and management of the vitamin-K-antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 204–33. [PubMed 15383473]
  • 20. Kearon C, Hirsh J: Management of anticoagulation before and after elective surgery. N Engl J Med 1997; 336: 1506–11. [PubMed 9154771]
  • 21. Kearon C: Long-term management of patients after venous thromboembolism. Circulation 2004; 110: 10–8. [PubMed 15339876]
  • 22. Katholi RE, Nolan SP, McGuire LB: The management of anticoagulation during noncardiac operations in patients with prosthetic heart valves. A prospective study. Am Heart J 1978; 96: 163–5. [PubMed 676976]
  • 23. Spandorfer JM, Lynch S, Weitz HH, Fertel S, Merli GJ: Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol 1999; 84: 478–80. [PubMed 10468095]
  • 24. Johnson JA, Turpie AG: Temporary discontinuation of oral anticoagulants: role of low-molecular-weight heparin. Thromb Haemost 2001; 85: 2323.
  • 25. Ferreira I, Dos L, Tornos P, Nicolau I, Permanyer-Miralda G, Soler-Soler J: Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003; 89: 527–30. [PubMed 12695457]
  • 26. Omran H, Hammerstingl C, Schmidt H, Lüderitz B: Periinterventionelles Management bei oral antikoagulierten Patienten [Abstract L6]. Hämostaseologie 2005; 25(1): 1–54.
  • 27. Dunn A, Spyropoulos A, Sirko S, Turpie A: Perioperative bridging therapy with enoxaparin in patients requiring interruption of long term anticoagulant therapy: a multicentre cohort study. Blood 2004; 104(abstract) 1761.
  • 28. Hammerstingl C, Schlang G, Bernhardt P, Schmidt H, Omran H: Einsetzbarkeit niedermolekularer Heparine bei Umstellung einer oralen Antikoagulation vor Interventionen mit erhöhtem Blutungsrisiko: Das „Bonn-Register“ – Erfahrungen mit 200 Patienten. Z Kardiol 2004; 93(Suppl): 281–2.
  • 29. Kovacs MJ, Kearon C, Rodger M et al.: Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin. Circulation 2004; 110: 1658–63. [PubMed 15364803]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun